comparemela.com

Latest Breaking News On - Vr adviser - Page 2 : comparemela.com

Viridian Therapeutics (NASDAQ:VRDN) Earns "Buy" Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a $30.00 target price on the stock. Other equities analysts have also issued research reports about the stock. Oppenheimer increased their target price […]

Canada
Blackrock
Nova-scotia
Viridian-therapeutics-inc
Vanguard-group-inc
Needham-company
Blackrock-inc
Fairmount-funds-management-llc
Vr-adviser
Royal-bank
Securities-exchange-commission

Chardan Capital Increases Dyne Therapeutics (NASDAQ:DYN) Price Target to $31.00

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target hoisted by Chardan Capital from $20.00 to $31.00 in a research note issued to investors on Friday, Stock Target Advisor reports. The brokerage currently has a buy rating on the stock. Several other research firms have also weighed in on DYN. StockNews.com upgraded shares of […]

United-states
Piper-sandler
Raymond-james
Oxana-beskrovnaya
Dirk-kersten
Stifel-nicolaus
Securities-exchange-commission
Dyne-therapeutics-inc
Blackrock-inc
Fcpm-iii-services
Goldman-sachs-group-inc
Vr-adviser

Adverum Biotechnologies (NASDAQ:ADVM) Downgraded by StockNews.com

Adverum Biotechnologies (NASDAQ:ADVM) Downgraded by StockNews.com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

James-paul-scopa
Vr-adviser
Adverum-biotechnologies-inc
Nasdaq
Newtyn-management
Adverum-biotechnologies-company-profile
Mirabella-financial-services
Securities-exchange-commission
Citigroup-inc
Adverum-biotechnologies
Free-report
Biotechnologies-trading-down

Dyne Therapeutics' (DYN) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $36.00 target price on the stock. HC Wainwright also issued estimates for Dyne Therapeutics’ Q1 2024 earnings at ($0.83) EPS, Q2 2024 earnings at ($0.83) […]

United-states
Stifel-nicolaus
Piper-sandler
Wildon-farwell
Raymond-james
Richard-william-scalzo
Fcpm-iii-services
Dyne-therapeutics-company-profile
Dyne-therapeutics-inc
Vr-adviser
Frazier-life-sciences-management
Dyne-therapeutics

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $76,245.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $76,245.00 in Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Manish-patel
Blackrock-inc
Vanguard-group-inc
Nasdaq
Citadel-advisors
Enliven-therapeutics-inc
Vr-adviser
Securities-exchange-commission
Enliven-therapeutics
Get-free-report
Exchange-commission
Therapeutics-trading-down
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.